Short Interest in Invivyd, Inc. (NASDAQ:IVVD) Increases By 8.4%

Invivyd, Inc. (NASDAQ:IVVD) saw a large increase in short interest in December. As of December 31st, there was short interest totalling 3,980,000 shares, an increase of 8.4% from the December 15th total of 3,670,000 shares. Currently, 5.3% of the company’s stock are sold short. Based on an average daily volume of 958,500 shares, the short-interest ratio is presently 4.2 days.

Insider Buying and Selling

In other Invivyd news, Director Terrance Mcguire sold 119,805 shares of the business’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $0.42, for a total value of $50,318.10. Following the transaction, the director now owns 3,568,274 shares of the company’s stock, valued at approximately $1,498,675.08. The trade was a 3.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 816,466 shares of company stock worth $423,214 in the last ninety days. Corporate insiders own 17.90% of the company’s stock.

Hedge Funds Weigh In On Invivyd

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. State Street Corp boosted its stake in shares of Invivyd by 3.7% during the 3rd quarter. State Street Corp now owns 1,018,640 shares of the company’s stock worth $1,039,000 after acquiring an additional 35,904 shares during the last quarter. Marshall Wace LLP raised its position in Invivyd by 4.2% during the second quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock valued at $866,000 after purchasing an additional 31,992 shares during the period. Duquesne Family Office LLC bought a new stake in Invivyd in the second quarter worth $629,000. Renaissance Technologies LLC purchased a new stake in shares of Invivyd in the second quarter valued at $421,000. Finally, Bank of New York Mellon Corp bought a new stake in Invivyd in the second quarter worth about $263,000. Institutional investors own 70.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on IVVD shares. HC Wainwright cut their target price on shares of Invivyd from $15.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, November 20th. EF Hutton Acquisition Co. I upgraded Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. D. Boral Capital reissued a “buy” rating and issued a $9.00 price target on shares of Invivyd in a report on Friday, January 10th. Finally, Morgan Stanley dropped their target price on Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research report on Wednesday, November 20th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $7.89.

Invivyd Price Performance

Shares of NASDAQ:IVVD opened at $0.41 on Friday. The business has a fifty day moving average price of $0.58 and a 200-day moving average price of $0.88. Invivyd has a 1-year low of $0.38 and a 1-year high of $5.20. The company has a market capitalization of $48.61 million, a PE ratio of -0.21 and a beta of 0.64.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.